Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Dana-Farber Cancer Institute, Boston, MA, United States



Survival: 5.1 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Boston, MA
   
Hospital: Dana-Farber Cancer Institute
   
Journal: Link
   
Date: 8/2014

Description:
Patients:
This study involved 12 relapsed/refractory peripheral T cell lymphoma patients. The median patient age was 70.7 years and 50% were male.

Treatment:
Patients received biologic therapy with imatinib mesylate, a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included lymphopenia, and thrombocytopenia.

Results:
The median overall survival was 5.1 months.

Correspondence: Dr. Eric Jacobsen; email: Eric_Jacobsen@dfci.harvard.edu

E-mail to a Friend Email Physician More Information